Image credit: Canva
Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Researchers want to know how two currently used treatments — pembrolizumab and the HPV vaccine PRGN-2009 — might work together against newly diagnosed cancer of the tonsil or tongue base prior to surgery or radiation therapy. A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching this combination therapy for such cancers.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Marissa B. Mallek, R.N., at (240) 760-7498 or marissa.mallek@nih.gov.
Clinicaltrials.gov identifier: NCT05996523
NCI Protocol ID: IRB001536
Official Title: Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.